Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C68H105N11O15 |
Molecular Weight | 1316.626 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 12 / 12 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]([C@@H](C)CC)([C@@H](CC(=O)N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C2=CC=CC=C2)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN4C(=O)C=CC4=O)C(C)C)C=C3)C(C)C
InChI
InChIKey=NLMBVBUNULOTNS-HOKPPMCLSA-N
InChI=1S/C68H105N11O15/c1-15-43(8)59(51(92-13)38-55(83)78-37-23-27-50(78)61(93-14)44(9)62(85)71-45(10)60(84)47-24-18-16-19-25-47)76(11)66(89)57(41(4)5)75-65(88)58(42(6)7)77(12)68(91)94-39-46-29-31-48(32-30-46)72-63(86)49(26-22-35-70-67(69)90)73-64(87)56(40(2)3)74-52(80)28-20-17-21-36-79-53(81)33-34-54(79)82/h16,18-19,24-25,29-34,40-45,49-51,56-61,84H,15,17,20-23,26-28,35-39H2,1-14H3,(H,71,85)(H,72,86)(H,73,87)(H,74,80)(H,75,88)(H3,69,70,90)/t43-,44+,45+,49-,50-,51+,56-,57-,58-,59-,60+,61+/m0/s1
VcMMAE (valine-citrulline-MMAE) is a drug-linker conjugate for antibody-drug conjugates (ADC) with potent antitumor activity by using the anti-mitotic and cytotoxic drug, monomethyl auristatin E (MMAE). MMAE is linked via the lysosomally cleavable dipeptide, valine-citrulline (vc), which can be specifically hydrolyzed by endosomal proteases, such as cathepsin B. ADCs developed using the valine-citrulline-MMAE (vc-MMAE) platform are studied for the treatment of different types of cancers.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07858 Gene ID: 1508.0 Gene Symbol: CTSB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27563235 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27563235
It was evaluated the cytotoxic effect of the FGF1V–vcMMAE conjugate on FGFR-expressing cells, including a model human fibroblast cell line, BJ. To test whether the cytotoxic effect is specific to FGFR-expressing cells, we employed a model system of U2OS and U2OS FGFR1 cells (stably transfected with the FGFR1) in which otherwise identical osteosarcoma cells lacking and expressing FGFRs can be compared. All the cell lines were treated with increasing concentrations (1*10(-9) – 1*10(-5) M) of the conjugate, FGF1V, or vcMMAE for 96 hours, and then their viability was assessed by the alamarBlue assay or counting in trypan Blue stain. As the maximum cytotoxic effect of both vcMMAE and FGF1V–MMAE was reached after 72–96 hours, the cytotoxicity assessment was performed after 96 hours of treatment.
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
646502-53-6
Created by
admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
|
PRIMARY | |||
|
46944733
Created by
admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
|
PRIMARY | |||
|
026S2O80A8
Created by
admin on Sat Dec 16 05:44:33 GMT 2023 , Edited by admin on Sat Dec 16 05:44:33 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD